CRX rs121918228: Cone-Rod Dystrophy and Retinal Function
The rs121918228 variant is an extremely rare missense substitution located in the homeodomain region of the CRX gene on chromosome 19. It is classified in clinical genetics databases as pathogenic for autosomal dominant cone-rod dystrophy (CORD2), a progressive inherited retinal disorder that affects central vision and color perception. Because CRX encodes an essential transcription factor for photoreceptor development, alterations in this critical functional domain can severely impair normal retinal maintenance.
What each genotype means
Typical vision risk
You carry two copies of the standard reference allele for this position in the CRX gene. This genotype is not associated with the rare inherited retinal disorders or cone-rod dystrophy linked to pathogenic homeodomain alterations. General population baseline risks for eye health and vision still apply.
Carried by more than 99.99% of individuals across all global populations.
Elevated cone-rod dystrophy risk
You carry one copy of the rare CRX homeodomain missense variant, which research associates with autosomal dominant cone-rod dystrophy and related retinal degenerations. Studies show this alteration can impair photoreceptor development and maintenance, often leading to progressive central visual acuity loss, decreased color perception, and light sensitivity. Because clinical presentation and age of onset can vary widely among individuals with CRX variants, these findings represent an elevated statistical risk profile rather than a definitive timeline of disease.
Extremely rare; observed in fewer than 1 in 100,000 individuals globally in gnomAD.
Genetic Overview and Molecular Identity
The variant cataloged as rs121918228 represents a single nucleotide variation within the CRX (cone-rod homeobox) gene, situated on the long arm of chromosome 19 at cytogenetic band 19q13. The CRX gene consists of coding exons that provide instructions for a nuclear homeodomain protein vital to ocular physiology. Biochemically, rs121918228 leads to a missense substitution that alters a conserved amino acid residue within the protein's DNA-binding homeodomain. Because the homeodomain coordinates precise sequence-specific recognition of downstream retinal target promoters, amino acid substitutions in this segment typically disrupt normal transcriptional activation or create dominant-negative interactions with wild-type proteins.
Biological Role of the CRX Transcription Factor
CRX is a specialized master transcription factor predominantly expressed in photoreceptor cells, including both rods and cones, as well as the pineal gland. It plays an indispensable role during embryonic and postnatal ocular development by orchestrating the differentiation and terminal maturation of photoreceptors. Beyond developmental stages, continuous expression of the CRX protein is essential to drive structural and phototransduction genes, such as rhodopsin and cone opsins, ensuring ongoing maintenance of the sensory retina. Without functional homeobox-mediated gene regulation, photoreceptors gradually lose their structural integrity and undergo progressive apoptotic degeneration.
Associated Retinal Phenotypes and Evidence Strength
Pathogenic variants in CRX are associated with a spectrum of inherited retinal dystrophies, notably cone-rod dystrophy 2 (CORD2), Leber congenital amaurosis 7 (LCA7), and occasionally retinitis pigmentosa. Genotype-phenotype studies indicate that missense variants localized specifically within the CRX homeodomain most frequently manifest as cone-rod dystrophy or macular dystrophy. Clinically, patients with autosomal dominant cone-rod dystrophy often experience childhood- or early adult-onset reduction in central visual acuity, photophobia, impaired color discrimination, and subsequent loss of peripheral vision. While individual case reports and functional assays consistently demonstrate pathogenic impact, the variant is rare, meaning population-scale evidence remains limited to small family pedigrees and targeted diagnostic cohorts.
Population Distribution and Rarity
Data from large-scale genomic reference initiatives, including the Genome Aggregation Database (gnomAD), show that rs121918228 is an exceptionally scarce allele, with an overall population frequency estimated at under 0.00001 (less than 1 in 100,000 individuals). The vast majority of people globally carry two copies of the common reference allele. Because CRX-associated retinal dystrophies follow an autosomal dominant transmission pattern or arise as spontaneous de novo mutations, pathogenic variants do not persist at significant polymorphic frequencies in healthy reference populations and are generally identified only through targeted diagnostic sequencing in individuals presenting with progressive visual deficits.
Interpreting Genetic Findings and Next Steps
Direct-to-consumer genetic assays and raw genotyping files are not intended for clinical diagnosis, as rare pathogenic homeodomain variants require high-fidelity diagnostic confirmation via clinical-grade Sanger or targeted next-generation sequencing. Finding this variant in a diagnostic setting does not serve as a treatment directive on its own; instead, it establishes an underlying molecular etiology for retinal degeneration. Any individual who carries or is suspected of carrying a CRX variant should consult an ophthalmologist specializing in inherited retinal diseases along with a board-certified genetic counselor to discuss electroretinography, low-vision support, family inheritance risks, and emerging clinical trials.
How common is this variant?
The rs121918228 variant is an extremely rare allele with a gnomAD population frequency under 0.00001 across all reported ancestries, with virtually all individuals worldwide homozygous for the reference allele.
Frequently asked questions
What eye conditions are associated with CRX rs121918228?
This variant is primarily associated with cone-rod dystrophy 2 (CORD2), an inherited retinal condition causing deterioration of rod and cone photoreceptor cells. It may also overlap with phenotypes of other retinal dystrophies, such as macular dystrophy or severe early-onset retinal degeneration.
How is a condition linked to rs121918228 inherited?
Retinal dystrophies caused by CRX mutations are most often inherited in an autosomal dominant pattern, meaning a single altered copy of the gene can be sufficient to cause disease. However, cases can also arise de novo, representing a new mutation in an individual with no prior family history.
Can consumer DNA kits reliably diagnose a CRX mutation?
No, commercial ancestry or health screening platforms frequently have higher error rates for extremely rare variations and do not substitute for clinical genetic sequencing. Any unexpected finding in raw genomic data should be validated through a certified medical laboratory under the guidance of a physician.
Are there medical treatments available for CRX-related vision loss?
Currently, there is no definitive cure for CRX-mediated cone-rod dystrophy, but clinical management focuses on regular ophthalmic evaluations, refractive correction, tinted lenses for photophobia, and low-vision aids. Identifying a specific molecular mutation can also help individuals qualify for investigational gene-therapy trials as they develop.
Sources & further reading
Educational information only, last refreshed 9/14/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121918228?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29